Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis

T Chen, N Zhang, MS Moran, P Su, BG Haffty… - Clinical breast …, 2018 - Elsevier
Endocrine responsiveness of primary breast cancers with borderline estrogen receptor
expression (ER+[1%-9%]) remains unclear. We aimed at investigating differences in …
被引用次数：78 相关文章

Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis.

T Chen, N Zhang, MS Moran, P Su, BG Haffty… - Clinical Breast …, 2017 - europepmc.org
Endocrine responsiveness of primary breast cancers with borderline estrogen receptor
expression (ER+[1%-9%]) remains unclear. We aimed at investigating differences in …

Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis

T Chen, N Zhang, MS Moran, P Su… - Clinical breast …, 2018 - pubmed.ncbi.nlm.nih.gov
Endocrine responsiveness of primary breast cancers with borderline estrogen receptor
expression (ER+[1%-9%]) remains unclear. We aimed at investigating differences in …

Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis

T Chen, N Zhang, MS Moran, P Su… - Clinical Breast …, 2018 - clinical-breast-cancer.com
Endocrine responsiveness of primary breast cancers with borderline estrogen receptor
expression (ER+[1%-9%]) remains unclear. We aimed at investigating differences in …

Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis

T Chen, N Zhang, MS Moran, P Su… - Clinical Breast …, 2018 - researchwithrutgers.com
Endocrine responsiveness of primary breast cancers with borderline estrogen receptor
expression (ER+[1%-9%]) remains unclear. We aimed at investigating differences in …